AMN Healthcare Services Stock (NYSE: AMN)

AMN Healthcare Services Stock (NYSE:AMN), Trade Ideas

AMN Healthcare Services

AMN Healthcare Services is one of the largest healthcare staffing company in the United States. In 2023, it offered more than 13,000 nurses and allied healthcare full-time workers with provider clients nationwide. About two thirds of its business is generated from its temporary nursing division; the other third is generated from its physician placement and technology-backed workplace solutions divisions.

Long Ideas

News

Markets

Media

Trading Ideas

CVNA

HUBS

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said  Carvana Co.  (NYSE: CVNA) has had a &#34;very, very big move now, I think Ernie Garcia [CEO of Carvana] is doing a terrific job.

This Tech Company Is One Of Cramer&#39;s &#39;Absolute Stocks... If It Gets Hit, Buy More&#39;

Penny Stocks

Small Cap

Intraday Update

Movers

AMAT

AMBO

AORT

AUUD

BLZE

CHNR

COIN

CPOP

DASH

DTSS

GXAI

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HTOO

IREN

JXJT

KNSL

LICN

LUNR

MERC

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NNOX

Nuveen California Dividend Advantage Municipal Fund 2

PRAA

ROKU

SPWR

SRPT

TANH

TCTM

TOST

TRUP

TVGN

TXRH

WEST

YELP

Shares of  DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.

Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Equities

AMN Healthcare Services Inc (NYSE: AMN), a total talent solutions provider for healthcare organizations, has 

AMN Healthcare Acquires MSDR For $300M, Expanding Locum Tenens Potential And Bolstering Talent Pool

AMN Healthcare Services Inc

ETRACS Alerian Midstream Energy Index ETN

American National Bankshares, Inc. (Danville, VA) Com

Amincor Inc

UBS AG ETRACS Alerian Midstream Energy High Dividend Index ETN

AMERICAN GREEN GROUP INC by American Green Group, Inc.

ARMANINO FOODS DIST INC by Armanino Foods of Distinction, Inc.

Armanino Foods of Distinction Inc

AMERICAN NOBLE GAS INC by American Noble Gas Inc.

American Noble Gas Inc

APPLIED MINERALS INC by Applied Minerals, Inc.

Applied Minerals Inc

AMCOMRI ENTERTAINMENT INC by Amcomri Entertainment Inc.

Amcomri Entertainment Inc

AMERICAN SIERRA GOLD CORP by American Sierra Gold Corp.

American Sierra Gold Corp

ASIA CMNT HLDGS CORP ORD by Asia Cement (China) Holdings Corp

Asia Cement (China) Holdings Corp

Ambrian PLC

<p>Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent halving event could lead to a scenario where demand for the cryptocurrency surpasses its supply by up to five times, as per a fresh analysis by <strong>Bitfinex</strong>.</p>
<p><strong>What Happened</strong>: Bitfinex&#8217;s analysts have suggested that the halving of Bitcoin&#8217;s mining rewards might lower the total value of new coins entering the market each day to around $30 million, CoinDesk <a href="https://www.coindesk.com/markets/2024/04/23/bitcoins-post-halving-demand-to-be-5x-greater-than-supply-bitfinex-estimates/">reported</a> on Tuesday. This is five times less than the daily average demand for U.S. spot ETFs.</p>
<p>&#8220;With the daily issuance rate declining post-halving, we estimate that the new supply added to the market (new BTC mined) would amount to approximately $40-$50 million in USD-notional terms based on issuance trends,&#8221; the Bitfinex analysts stated.</p>
<p>Post-halving, the total number of new coins added to the supply daily has dropped to 450 BTC (nearly $30 million) from the pre-halving four-year average of around 900 BTC, according to data from Glassnode.</p>
<p><em>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38346512/benzinga-bulls-and-bears-tesla-draftkings-broadcom-and-trader-says-buy-dogecoin-in-high-10?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla, Draftkings, Broadcom And Trader Says Buy Dogecoin In High 10 Cents: Benzinga Bulls And Bears</a></em></p>
<p>Bitfinex also observed that investors are increasingly opting to take direct custody of their coins, which further weakens the market&#8217;s supply side.</p>
<p>&#8220;Current on-chain data indicates that Bitcoin exchange outflows are reaching peaks not seen since January 2023, suggesting that many investors are moving their holdings to cold storage in anticipation of price increases&#8221; the analysts said.</p>
<p>At the time of reporting, Bitcoin was trading at $66,548.30, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><strong>Why It Matters</strong>: The <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38345043/bitcoin-shrugs-off-fourth-halving-miner-rewards-halved-price-holds-strong">recent halving event,</a> which saw the reward for mining a block drop from 6.25 BTC to 3.125 BTC, is a programmed process in the Bitcoin protocol designed to manage scarcity and regulate the inflationary supply of Bitcoin. This process effectively slows down the rate at which new Bitcoin is created.</p>
<p>Following the halving, Bitcoin transaction fees have significantly decreased, <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38348912/bitcoin-transaction-fees-dive-to-5-year-low-following-halving">reaching a five-year low</a>. This drop comes despite the launch of the Runes token standard, which initially caused a surge in transaction costs.</p>
<p>Furthermore, <strong>Cathie Wood's Ark Invest </strong>has suggested that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38372445/cathie-woods-ark-invest-says-bitcoin-could-be-priming-for-over-3-000-rally-over-nex">Bitcoin could be primed for a rally </a>of over 3,000% over the next 12 months, as the cryptocurrency becomes less inflationary than gold following the halving.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38349928/melania-trump-launches-245-customizable-mothers-day-necklace-buyers-to-also-get-limited-ed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Melania Trump Launches $245 Customizable Mother&#8217;s Day Necklace, Buyers To Also Get Limited-Edition Solana</a></em></p>
<p><em>Image via Shutterstock</em></p>
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>
<p style="font-family: sans-serif;padding-top: 20px">
            Engineered by <span style="font-weight: bold;text-decoration: none;color: #225aa9;font-size: 1rem">Benzinga Neuro</span>, Edited by <span style="font-weight: bold;text-decoration: none;color: #225aa9;font-size: 1rem"><br />
                <u><a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a></u><br />
            </span>
        </p>
<hr style="border: 0;height: 1px;background: #225aa9" />
<p style="font-family: sans-serif;padding-top: 20px">
            The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.<br />
            <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
        </p>
<hr style="border: 0;height: 5px;background: #225aa9" />
    </div>
</div>


Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Analyst Ratings

General

$BTC

Bitcoin's Demand Set To Outpace Supply By Fivefold After Recent Halving: Bitfinex Analysis

<p><strong>Fiserv,&nbsp;Inc&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>)&nbsp;reported&nbsp;fiscal first-quarter results, with revenue increasing by 7%&nbsp;Y/Y&nbsp;to $4.88 billion, beating the consensus of $4.57 billion. Adjusted revenue increased&nbsp;7%&nbsp;Y/Y&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38375134/fiserv-reports-first-quarter-2024-results" rel="noreferrer noopener">to $4.54 billion</a>.&nbsp;</p>
<p>Adjusted EPS of $1.88 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.79</a>.&nbsp;This&nbsp;is a 19% increase over $1.91 from&nbsp;the same period&nbsp;last year.&nbsp;The&nbsp;stock price gained after the print.</p>
<p>Organic revenue grew 20%, led by 23% growth in the Merchant Solutions segment and 5% in the Financial Solutions segment.</p>
<p>The adjusted operating margin increased by 180 bps Y/Y to 35.8%.&nbsp;Adjusted operating margin increased 440 basis points Y/Y to 34.1% in the Merchant Solutions segment and 160 basis points Y/Y to 44.1% in the Financial Solutions segment.</p>
<p> &#8220;This proven model, along with our strong first quarter results, led us to raise our 2024 adjusted earnings per share outlook for the full year,&#8221; <strong>Frank Bisignano</strong>, chairman, president and chief executive officer of Fiserv said.</p>
<p><strong>FY24 Outlook:</strong>&nbsp;Fiserv&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/02/36953903/whats-going-on-with-fiserv-stock-tuesday" rel="noreferrer noopener">reiterated organic revenue</a>&nbsp;growth of 15%-17% and raised adjusted EPS outlook to $8.60 &#8211; $8.75 (prior $8.55 &#8211; $8.70), representing&nbsp;growth of 14%-16% Y/Y versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$8.63 consensus</a>.</p>
<p>Fiserv stock has gained 27% in the last 12 months. </p>
<p><strong>Price Action:</strong> FI shares were up 5.6% at $157.17 at last check Tuesday.</p>
<p><em>Photo: Shutterstock</em></p>


Earnings

Guidance

Fiserv Reports 'Strong First Quarter Results,' Raises Full-Year Outlook

Verizon shares are trading higher following Monday's earnings report.

<p>JMP Securities  analyst Aaron Hecht   reiterates Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Market Outperform and maintains $150 price target.</p>


Price Target

Reiteration

JMP Securities Reiterates Market Outperform on Sun Communities, Maintains $150 Price Target

<p><strong>Innocan Pharma Corporation </strong>(CSE:<a class="ticker" href="https://www.benzinga.com/stock/INNO#CSE">INNO</a>) (FSE: IP4) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/INNPF#OTCQB">INNPF</a>) announced on Monday that it has submitted its letter of application for a<strong> Pre-IND meeting with the U.S. Food and Drug Administration (FDA), for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.</strong></p>
<p>With the move, the company initiated the regulatory process with the FDA for the approval of its prolonged CBD release technology for human use.</p>
<h3 class="wp-block-heading">Why It Matters</h3>
<p>"Innocan&#8217;s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of its LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions," the company said in a press release.</p>
<p><strong>Iris Bincovich</strong>, CEO of Innocan, explained what the move means for Innocan.</p>
<p>"This is a key milestone for Innocan and marks our first step towards the FDA&#8217;s recognition of our technology," Bincovich said. "We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.&#8221;</p>
<p>Meanwhile, the<strong> </strong>innovative treatment is an alternative to opioid-based approaches to treating chronic pain.</p>
<p>In a recently published groundbreaking study, researchers weighed the pain-alleviating potential of medical marijuana versus opioids, showing that cannabis is similarly effective as opioids and traditional pain meds <a href="https://www.benzinga.com/markets/cannabis/24/01/36578723/huge-study-reveals-cannabis-provides-similar-pain-relief-benefits-as-opioids-without-negative-co">for the treatment of non-cancer pain.</a></p>
<p><em>See also: <a href="https://www.benzinga.com/markets/cannabis/24/03/37941713/cbd-a-potent-alternative-for-dental-pain-management-says-study">CBD A Potent Alternative For Dental Pain Management, Says Study</a></em></p>
<p>Moreover, many people are struggling with opioid use disorder (OUD). Fentanyl, an opioid used as a pain medication, is considered dangerous, addictive and one of the reasons why rates of drug overdose deaths are skyrocketing.</p>
<p>According to CDC <a href="https://www.cdc.gov/opioids/basics/fentanyl.html">data</a>, overdose deaths caused by synthetic opioids other than methadone, including fentanyl and fentanyl analogs, <a href="https://www.benzinga.com/markets/cannabis/22/12/30022658/this-new-fentanyl-overdose-reversal-drug-is-stronger-than-narcan-heres-why">increased by over 56% from 2019 to 2020.</a></p>
<h3 class="wp-block-heading">What's Next</h3>
<p>Innocan said at the Pre-IND meeting that it will focus on obtaining guidance from the FDA on the preclinical and clinical development plan thus enabling the initiation of an Investigational New Drug (IND) program in the country.</p>
<p>"We believe that Innocan&#8217;s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain,&#8221; said Dr. <strong>Joseph Pergolizzi,</strong> Innocan&#8217;s FDA advisory board member.</p>
<p><em>Now read: <a href="https://www.benzinga.com/markets/cannabis/24/02/37104612/cbd-focused-pharma-co-innocan-reveals-433-yoy-increase-in-2023-revenue-as-it-pursues-fda-approva">CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval</a></em></p>


Cannabis

Health Care

CSE:INNO

INNO

INNPF

This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain

<ul>
<li>GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave&#39;s next generation GalNAc-siRNA format with potential for best-in-class potency and durability</li>
<li>GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas</li>
<li>Wave is on track to initiate a clinical trial of its wholly owned INHBE program for obesity in 1Q 2025, which also uses the company&#39;s next generation siRNA</li>
</ul>


Biotech

Large Cap

Contracts

As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M

<p>The latest indications on U.S. private sector activity reveal a sharp and unexpected slowdown in the pace of growth in April 2024, marking the softest <a href="https://www.benzinga.com/topic/economics">expansion since December 2023.</a></p>
<p>A positive takeaway from the flash Purchasing Managers Index (PMI) surveys released Tuesday by S&amp;P Global is the welcome moderation in the rates of increase for selling prices in both goods and services observed in April.</p>
<h3 class="wp-block-heading">Global&#8217;s Flash PMIs For April 2024: Key Takeaways</h3>
<ul>
<li>The U.S. Composite PMI decelerated from 52.1 to 50.9, marking a four-month low. Nevertheless, April signaled the 15th consecutive month of output increase. </li>
<li>The U.S. Services PMI fell from 51.7 to 50.9, missing expectations of a rise to 52, marking a five-month low. </li>
<li>The U.S. Manufacturing PMI fell from 51.9 to 49.9, falling short of the 52 forecasted, hitting a four-month low. </li>
<li>Output growth moderated in accordance with weakened demand as new orders decreased for the first time in six months.</li>
<li>Companies reduced employment for the first time in nearly four years, while business confidence also declined to its lowest level since last November.</li>
<li>Inflation rates generally eased at the beginning of the second quarter, with both input costs and output prices rising at a slower pace overall. Manufacturing input cost inflation reached a one-year high.</li>
</ul>
<h3 class="wp-block-heading">Economist Reactions</h3>
<p>&#8220;The US economic upturn lost momentum at the start of the second quarter,&#8221; said <strong>Chris Williamson</strong>, chief business economist at S&amp;P Global Market Intelligence. </p>
<p>&#8220;Further pace may be lost in the coming months, as April saw inflows of new business fall for the<br />first time in six months and firms' future output expectations slipped to a five-month low amid heightened concern about the outlook,&#8221; he added. </p>
<p>Tougher business conditions led companies to reduce their workforce at a rate not seen since the global financial crisis, excluding the early pandemic lockdown months, he said.</p>
<p>Lower demand and a cooling labor market resulted in reduced price pressures, with April showing a welcome slowdown in the rate of price increases for both goods and services.</p>
<p>Notably, the drivers of inflation have changed. Manufacturing has now registered the steeper rate of<br />price increases in three of the past four months, with factory cost pressures intensifying in April amid higher raw material and fuel prices, contrasting with the wage-related, services-led price pressures seen throughout much of 2023," Williamson stated. </p>
<h3 class="wp-block-heading">Market Reactions</h3>
<p>The U.S. dollar index (DXY), as tracked by the <strong>Invesco DB USD Index Bullish Fund ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), fell 0.4%, hit by the decline in Treasury yields. </p>
<p>The yield in the policy-sensitive two-year Treasury note softened by 5 basis points to 4.94%.</p>
<p>Stocks positively reacted, with the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) up 0.8% in early trading Tuesday. </p>
<p>Tech stocks, as tracked by the <strong>Invesco QQQ Trust</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), outperformed, up 1%. </p>
<p>Gold witnessed a rebound of 0.4% after closing Monday its <a href="https://www.benzinga.com/news/large-cap/24/04/38364875/geopolitical-relief-triggers-gold-selloff-prices-dip-below-2-350-mark-mining-stocks-hit-hard">worst-performing day in years.</a> </p>
<p>Read now: <em><a href="https://www.benzinga.com/markets/asia/24/04/38380008/us-mulls-sanctions-on-beijing-banks-for-alleged-role-in-putins-war-in-ukraine-china-cant-have-it-bot">US Mulls Sanctions On Beijing Banks For Alleged Role In Putin&#8217;s War In Ukraine: &#8216;China Can&#8217;t Have It Both Ways,&#8217; Blinken Says</a></em></p>
<p><em>Photo via Shutterstock. </em></p>


Macro Notification

Broad U.S. Equity ETFs

Treasuries

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

US Private Sector Growth Unexpectedly Slows In April, Marks Lowest Increase In 4 Months: 'Drivers Of Inflation Have Changed'

<p>The U.S. Supreme Court is set to hear a challenge from <strong>Starbucks Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) against the National Labor Relations Board&#8217;s decision to reinstate fired baristas who were organizing a union.</p>
<p><strong>What Happened</strong>: The case stems from a 2022 incident where Starbucks fired seven baristas from a Memphis coffeehouse for violating company policy by inviting a TV news crew into the store after hours, The Washington Post <a href="https://www.washingtonpost.com/business/2024/04/23/starbucks-union-supreme-court/">reported</a> on Monday. The workers claimed they were fired for their union activities, a claim the National Labor Relations Board (NLRB) agreed with. </p>
<p>A federal judge approved the NLRB&#8217;s request for an order to reinstate the workers, a decision upheld by an appeals court.</p>
<p>The case arrives at the Supreme Court amid ongoing negotiations between Starbucks and the local union, to withdraw ongoing litigation. However, Starbucks is disputing the standard used by federal judges to determine whether workers should be reinstated when requested by the NLRB.</p>
<p>The Supreme Court&#8217;s decision could potentially impact labor organizing across the country. Experts fear a ruling against the NLRB could weaken labor organizing in other scenarios. </p>
<p>&#8220;This could have a substantial impact,&#8221; said <strong>James Cooney,</strong> a labor studies professor at Rutgers University.</p>
<p>&#8220;If a stricter standard is adopted by the Supreme Court, it&#8217;ll be more difficult for the labor board to maintain the status quo for workers during an organizing drive.&#8221;</p>
<p><em>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38349807/bitcoin-signals-potential-67-gain-as-this-key-metric-dips-below-90-day-average-analyst-say?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Signals Potential 67% Gain As This Key Metric Dips Below 90-Day Average: Analyst Says &#8216;Perfect Ti</a></em></p>
<p><strong>Why It Matters</strong>: This case comes after a series of labor disputes at Starbucks. In November, the Workers United union <a href="https://www.benzinga.com/markets/equities/23/11/35771946/starbucks-faces-employee-walkout-at-hundreds-of-stores-on-red-cup-day-report">announced a strike involving thousands of employees </a>at numerous Starbucks locations on the company&#8217;s Red Cup day, a key promotional event during the holiday season and called for better pay, staffing, and schedules.</p>
<p>In December, Starbucks <a href="https://www.benzinga.com/markets/equities/23/12/36158710/starbucks-reportedly-reaches-out-to-union-a-fresh-start-for-worker-relations-in-new-year">reached out to the union representing hundreds of its stores</a> in the U.S. to improve its strained association with some of its frontline workers. The union represents over 9,000 Starbucks workers at about 360 U.S. stores. There had been over five months of inactivity in contract bargaining from the Workers United union.</p>
<p>In March, the Strategic Organizing Center (SOC), a shareholder of Starbucks, <a href="https://www.benzinga.com/markets/equities/24/03/37486213/coffeehouse-compromise-starbucks-shareholder-soc-pulls-director-nominations-amid-breakthrough-in">withdrew its director nominations,</a> believing that the recent agreement reached by Starbucks and Workers United represents meaningful progress that will benefit all stakeholders. The SOC started its campaign for change at Starbucks last November, believing that the company's response to its employees' attempts to unionize was misguided.</p>
<p><strong>Price Action: </strong>On Tuesday, Starbucks shares were trading at 88.20, indicating a 0.023% increase as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/equities/24/04/38346938/trump-is-a-force-of-nature-reince-priebus-has-raised-70m-for-gop-convention-despite-being-pushed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Trump Is A Force of Nature&#8217;: Reince Priebus Has Raised $70M For GOP Convention Despite Being Pushed Out</a></em></p>
<p><em>Photo by Manu Padilla on Shutterstock</em></p>
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>
<p style="font-family: sans-serif;padding-top: 20px">
            Engineered by <span style="font-weight: bold;text-decoration: none;color: #225aa9;font-size: 1rem">Benzinga Neuro</span>, Edited by <span style="font-weight: bold;text-decoration: none;color: #225aa9;font-size: 1rem"><br />
                <u><a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a></u><br />
            </span>
        </p>
<hr style="border: 0;height: 1px;background: #225aa9" />
<p style="font-family: sans-serif;padding-top: 20px">
            The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.<br />
            <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
        </p>
<hr style="border: 0;height: 5px;background: #225aa9" />
    </div>
</div>


SBUX

US Supreme Court To Weigh Starbucks Challenge Over Fired Baristas

WIIM

PepsiCo shares are trading lower following Q1 earnings.

CZOO

Cazoo Group Shares Resume Trade

Coinbase shares are trading higher as crypto stocks gain following the Bitcoin halving.

<p><strong>Philip Morris International Inc</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) reported first-quarter FY24 sales growth of 9.7% year-on-year to $8.793 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38374936/philip-morris-international-reports-first-quarter-2024-results-and-updates-full-year-guidance" rel="noreferrer noopener">beating the analyst consensus estimate of $8.468 billion</a>.</p>
<p>The smoke-free business accounted for 39% of the company's total net revenues.</p>
<p>Cigarette and Heated Tobacco unit (HTU) shipment volume in first-quarter grew by 3.1% Y/Y, reflecting growth of 20.9% for HTUs and a decline of 0.4% for cigarettes.</p>
<p>Adjusted EPS of $1.50 <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beat the consensus estimate of $1.41.</a></p>
<p>Marlboro<em>&nbsp;</em>cigarette shipment volume increased by 1.7% to 56.9 billion units. Revenue from smoke-free products increased 21.1% Y/Y to $3.4 billion.</p>
<p>Adjusted operating margin for the quarter expanded from 37.3% to 38.2%, with $3.36 billion in adjusted operating income.</p>
<p>The company held $3.9 billion in cash and equivalents as of March-end.</p>
<p>Jacek Olczak, Chief Executive Officer, said, &#8220;We are executing efficiently and effectively in a dynamic operating environment of geopolitical and economic tensions that accentuate currency volatility. We are doing our utmost to mitigate these challenges and deliver robust growth and value creation.&#8221;</p>
<p><strong>Outlook</strong>: Philip Morris cuts FY24 adjusted EPS outlook to $6.19 &#8211; $6.31&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/02/37015597/why-is-philip-morris-stock-falling-today" rel="noreferrer noopener">from&nbsp;$6.32-$6.44</a>&nbsp;versus an estimate of $6.35.</p>
<p>It raised FY24 organic revenue growth guidance to 7% &#8211; 8.5% from 6.5% &#8211; 8%.</p>
<p>Philip Morris sees second-quarter adjusted EPS of $1.50 &#8211; $1.55 against an&nbsp;estimate of&nbsp;$1.63.</p>
<p><strong>Price Action</strong>: PM shares are trading higher by 2.98% at $96.86 at the last check Tuesday.</p>
<p><em>Image by svklimkin from Pixabay</em></p>


Why Is Marlboro Maker Philip Morris Stock Shooting Higher Today?

<p>JP Morgan  analyst Jeremy Tonet   maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Neutral and raises the price target from $18 to $19.</p>


JP Morgan Maintains Neutral on PG&E, Raises Price Target to $19

MANH

Manhattan Associates Selects TeamViewer As Strategic Partner For Warehouse Vision Picking

<p>JMP Securities  analyst Matthew Carletti   reiterates RLI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) with a Market Perform.</p>


JMP Securities Reiterates Market Perform on RLI

<p>JP Morgan  analyst Ken Worthington   maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a Neutral and raises the price target from $31 to $35.</p>


Janus Henderson Group plc Ordinary Shares

JP Morgan Maintains Neutral on Janus Henderson Group, Raises Price Target to $35

Cazoo Group Shares Halted To The Downside, Stock Now Up 55.1%

<p>Good Morning Traders! In today&#39;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.</p>
<p>Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.</p>
<p>We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#39;s pulse to optimize your trading gains. Now, let&#39;s dive into the stock analysis:</p>
<h3><strong>SPDR S&amp;P 500 ETF Trust </strong></h3>
<p>The SPY (ARCA: SPY) is currently positioned around a price of 500.91. For those favoring upward movement, the first target is 501.74. Should the price remain robust above this mark, the next objective is to reach 502.85. Should this support endure throughout the regular trading hours, an advance beyond to 503.95 might occur. The ambitious target for bulls on SPY today stands at 505.32.</p>
<p>Conversely, if 500.91 fails to serve as a sturdy floor, a downward test towards 500.17 by the bears is anticipated. Presence of sellers could further pressure the price to a lower target of 498.93. If this threshold is breached amid strong selling activity, the next substantial support is 497.55. A tumultuous selling session might culminate in reaching a bearish extreme at 496.93 today.</p>
<h3><strong>Invesco QQQ Trust Series 1</strong></h3>
<p>The Q&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>) are trading near 420.76. Bullish traders aim to secure this level, setting sights on 422.16 as a substantial support if maintained. Following this, 423.27 might come into play if buying strength persists, with an ultimate test at 424.04. The highest bullish aim for today is set at 424.82.</p>
<p>Should the level of 420.76 not withstand selling pressures today, bears might dominate, pushing the price to 419.89. A subsequent weakness could prompt further tests at 418.49. If selling intensifies, 417.49 could be at risk. Failure to hold this could lead bears to drive the price down to today&rsquo;s bearish goal of 416.23.</p>
<h3><strong>Apple Inc.</strong></h3>
<p>Apple&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) is currently at 165.62, where bulls hope to establish support. A rally towards 166.27 is desired, with potential further uplift to 167.09 if bullish momentum continues. If bulls dominate today, the ultimate aim is to reach a high of 167.59.</p>
<p>If Apple&#39;s price can&#39;t sustain 165.62 as support, a decline to 164.71 might ensue. With continued selling, a further descent to 164.15 is likely. If selling persists, the price could fall to 163.24 and if this level breaks, the final bearish target for the day is set at 162.69.</p>
<h3><strong>Microsoft Corp.</strong></h3>
<p>Microsoft&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) current level is 402.74, with bulls looking to maintain and extend the price to 404.92 as a firm support. Success here could lead to a push towards 406.01, and with continued buying, a peak bull target of 407.11 might be in sight today.</p>
<p>However, if 402.74 does not hold, bears could drive the price down to 401.39. If this level is breached, further declines to 400.30 and then 399.21 could occur, with a final bearish objective for today at 397.65.</p>
<h3><strong>NVIDIA Corporation</strong></h3>
<p>NVIDIA&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) stands at 804.61, with bulls aiming for an initial rise to 810.13, securing it as a key support zone. A sustained buying push could elevate the price to 816.95, and potentially up to 823.52. The highest bull target today is envisioned at 827.98.</p>
<p>If 804.61 does not hold up, bears are expected to challenge the price down to 799.10. A breakdown here, with seller activity, could lead to 794.94. If weakness continues, further tests at 791.44 might occur, with a bearish floor target of 785.35 for the day.</p>
<h3><strong>Alphabet Inc Class A</strong></h3>
<p>Alphabet&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) is hovering around 156.61, with bulls hoping to secure this as a base for advancing to 157.41. With continued upward momentum, the next level to watch is 158.54.</p>
<p>If 156.61 cannot sustain support, a bearish push to 155.59 is likely. A break below this level might lead bears to 154.95, with a severe sell-off potentially bottoming out at 154.44 today.</p>
<h3><strong>Meta Platforms Inc </strong></h3>
<p>Meta&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) is currently positioned at 488.81. Bulls aim to keep the level supported for a rise to 492.33, followed by a potential increase to 495.54. If buying remains strong, the highest bull target for today is 498.03.</p>
<p>Conversely, if 488.81 fails as support, a downward move to 485.96 is expected. Persistent selling could further drive the price to 483.11. If this level is compromised, the lowest bear target for Meta today stands at 479.47.</p>
<h3><strong>Tesla Inc. </strong></h3>
<p>Tesla&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) starts the day at 141.94. Bulls are targeting an increase to 143.67 and, with sustained buying, further up to 145.07. Strong market conditions could see Tesla reaching a higher test at 146.46, with a peak bull target of 148.45.</p>
<p>If 141.94 does not maintain as a robust support, bears may test down to 139.15. Continued selling pressure could bring the price further down to 136.35, and if this level fails, the ultimate bear target for the day is 134.62.</p>
<p>Final Word: Today&#39;s session begins light on data in the premarket with the Philly Fed Non-Manufacturing Activity due out at 8:30AM ET, followed by the Redbook Retail Sales at 8:55AM ET. More significant data will follow with the Global Manufacturing, Services, and Composite PMI for April, scheduled for release at 9:45AM ET. Shortly after, at 10AM ET, the Richmond Fed Manufacturing Index and Business Conditions, alongside New Home Sales for March, will be available. At 1PM, a 2-Year Note Auction is set, which could introduce some volatility into the markets. As the Federal Reserve remains in a blackout period ahead of next Wednesday&#39;s FOMC rate decision, most large institutional traders will be focusing on earnings reports after today&#39;s closing bell from major companies like Tesla and Visa. Good luck and trade safely!</p>
<p>The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.</p>
<p>Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day&mdash;hours before it&#39;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.</p>
<p>For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.</p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.</em></p>


Tech

AAPL

GOOGL

MSFT

NVDA

TSLA

Market Clubhouse Morning Memo - April 23rd, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, And TSLA)

EBMT

Eagle Bancorp Montana Q1 2024 EPS $0.24 Down From $0.42 YoY; Revenue $19.2M Down From $21.1M YoY

<p>JP Morgan  analyst Steven Alexopoulos   maintains HBT Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBT#NASDAQ">HBT</a>) with a Underweight and raises the price target from $21 to $22.</p>


JP Morgan Maintains Underweight on HBT Finl, Raises Price Target to $22

Truist Financial analyst Tobey Sommer assigned a Buy rating to the stock today. The company's shares closed last Friday at $58.72. According to Tip...

Truist Financial Releases a Buy Rating on AMN Healthcare Services (AMN)

IXJ: Healthcare Sector Dashboard For March

In a report released today, Tobey Sommer from Truist Financial assigned a Buy rating to AMN Healthcare Services (AMN – Research Report). The compan...

In this recap of Friday's trading session, I discuss the various trades taken throughout the week and how the VIX has moved recently.

Masters In Trading - Saturday, March 23

Warning: AMN is at high risk of performing badly

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>With the market trading near all-time highs, undervalued <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.</p>



<p>As a <em>Reuters</em> report mentioned recently, publicly traded technology enterprises <a href="https://www.reuters.com/markets/us/global-markets-flows-bofa-urgent-2024-03-08/#:~:text=Tech%20stocks%20saw%20%244.4%20billion,far%20back%20its%20figures%20went.">witnessed a huge outflow of $4.4 billion</a>. In fact, it was the largest-ever outflow of funds over a single week. It&rsquo;s not hard to understand why. As artificial intelligence and other technologies boosted share prices, it makes sense to secure profits ahead of a possible correction.</p>



<p>At the same time, it&rsquo;s possible that certain underappreciated sectors could see inflows. With that, the below undervalued healthcare stocks present attractive upside prospects.</p>



<h2>Patterson Companies (PDCO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/pdco-stock-1-300x169.jpg" alt="An image of a phone displaying the Patterson Companies, Inc. (PDCO) logo"><div>Source: IgorGolovniov / Shutterstock.com</div></div><p>Falling under the medical distribution segment of undervalued healthcare stocks, <strong>Patterson Companies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pdco-stock-quote/"><strong>PDCO</strong></a>) engages in the distribution of dental and animal health products in the U.S., U.K. and Canada. Per its <a href="https://finance.yahoo.com/quote/PDCO/profile">public profile</a>, the company operates through three segments: Dental, Animal Health and Corporate.</p>



<p>While it&rsquo;s a relevant enterprise, its financial performances last year have been all over the map. For example, in the first quarter, Patterson posted earnings per share of 84 cents, handily beating the estimate targeting 70 cents. However, it missed the EPS targets for the back half of 2023, yielding a negative earnings surprise of 7.75%.</p>



<p>For fiscal 2024, expectations are somewhat muted, with experts calling for EPS of $2.32 on sales of $6.56 billion. Last year, the metrics were $2.42 on sales of $6.47 billion. However, the robust performance of the <a href="https://www.prnewswire.com/news-releases/us-pet-industry-reaches-147-billion-in-sales-in-2023-302097201.html">U.S. pet products and services industry</a> could help lift PDCO.</p>



<p>Currently, shares are only trade at a <a href="https://www.gurufocus.com/stock/PDCO/summary?search=pdco">forward earnings multiple of 10.84X</a>, below the sector median 15.8X.</p>



<h2>Bristol-Myers Squibb (BMY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/bmy1600b-300x169.jpg" alt="Bristol-Myers (BMY) logo at the top of a cellphone."><div>Source: Piotr Swat / Shutterstock.com</div></div><p>Falling under the drug manufacturing segment of undervalued healthcare stocks, <strong>Bristol-Myers Squibb</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/"><strong>BMY</strong></a>) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Per its <a href="https://finance.yahoo.com/quote/bmy/profile">corporate profile</a>, BMY offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. One of its main drugs is Opdivo for various anti-cancer indications.</p>



<p>Overall, BMY has been a reliable source of operational performance for stakeholders. Last year, the one glaring miss came in Q2. Back then, the company forwarded EPS of $1.75. However, Wall Street was anticipating earnings of $1.98 per share. Still, inclusive of the Q2 miss, the overall positive earnings surprise last year came out to just over 4%.</p>



<p>Moving forward, for fiscal 2024, analysts anticipate that EPS will land at $6.28 on revenue of $42.31 billion. Last year, BMY posted EPS of $6.91 on revenue of $41.42 billion.</p>



<p>Now, that might seem modest. However, shares are <a href="https://www.gurufocus.com/stock/BMY/summary?search=bmy">trading hands at only 7.37X forward earnings</a>. In contrast, drug manufacturers post a median forward multiple of 14.45X. Thus, BMY might be one of the undervalued healthcare stocks worth picking up.</p>



<h2>CVS Health (CVS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/cvs_pharmacy_cvs1600-300x169.jpg" alt="The logo for CVS Pharmacy is displayed on a retail storefront."><div>Source: Shutterstock</div></div><p>Falling under the healthcare plans subsegment, <strong>CVS Health</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/cvs-stock-quote/"><strong>CVS</strong></a>) represents one of the most recognizable brands in the broader industry. According to its <a href="https://finance.yahoo.com/quote/cvs/profile">public profile</a>, CVS operates through the Health Care Benefits, Health Services and Pharmacy &amp; Consumer Wellness segments. As a multi-tiered enterprise, it offers a wide canvas that could appeal to bargain hunters.</p>



<p>No, CVS stock hasn&rsquo;t exactly lit up the board. However, it deserves a second look for its consistent performances. Notably, the company beat EPS targets four times out of the last four quarters. The average positive earnings surprise came out to just over 5%. Also, it&rsquo;s worth mentioning that for Q2 2024, analysts have revised their expectations upward three times in the last 30 days.</p>



<p>For the current fiscal year, experts believe that EPS will land at $8.31 on revenue of $370.82 billion. Last year, CVS posted per-share profits of $8.74 on revenue of $357.78 billion.</p>



<p>Currently, shares trade hands at <a href="https://www.gurufocus.com/stock/CVS/summary?search=cvs">9.48X forward earnings</a>, below 85.71% of its peers. That seems overdone. Therefore, CVS ranks among the undervalued healthcare stocks to consider.</p>



<h2>AMN Healthcare Services (AMN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/amn1600-300x169.png" alt="AMN Healthcare Services website homepage. AMN Healthcare logo visible."><div>Source: Casimiro PT / Shutterstock.com</div></div><p>Operating under the medical care facilities segment, <strong>AMN Healthcare Services</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/amn-stock-quote/"><strong>AMN</strong></a>) represents one of the riskier undervalued healthcare stocks. Still, if the market gods smile on AMN, it could swing dramatically higher. Per its <a href="https://finance.yahoo.com/quote/amn/profile">corporate profile</a>, the company provides healthcare workforce solutions and staffing services to healthcare facilities in the U.S.</p>



<p>At first glance, AMN doesn&rsquo;t seem a bad idea. For example, in the most recent quarter, the company posted EPS of $1.32, beating the consensus view of $1.25. Overall, the average positive earnings surprise in fiscal 2023 clocked in at 10.6%. Strong performances in Q2 and Q3 helped pad the metric.</p>



<p>However, analysts anticipate a rough outing in fiscal 2024, projecting EPS of $3.96 on sales of $3.19 billion. In contrast, AMN posted per-share profits of $8.21 on revenue of $3.79 billion. Still, it might come down to a matter of appropriate pricing.</p>



<p>Currently, shares trade at 13.41X forward earnings, lower than 86.21% of sector rivals. Encouragingly, covering experts rate AMN a <a href="https://www.tipranks.com/stocks/amn/forecast">moderate buy</a> with a $78.25 price target, implying a robust upside.</p>



<h2>Royalty Pharma (RPRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div><p>Falling under the biotechnology sphere, <strong>Royalty Pharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rprx-stock-quote/"><strong>RPRX</strong></a>) operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry. From its <a href="https://finance.yahoo.com/quote/RPRX/profile">public profile</a>, Royalty is also involved in the identification, evaluation and acquisition of royalties on various biopharmaceutical therapies.</p>



<p>Generally speaking, RPRX stock doesn&rsquo;t generate much attention. That&rsquo;s even more the case following a rough outing in 2023. However, contrarians targeting undervalued healthcare stocks might want to give Royalty another look. It&rsquo;s surprisingly reliable, beating per-share profit estimates four times out of four last year. Indeed, the average positive earnings surprise stood at 11.88%.</p>



<p>For fiscal 2024, experts believe EPS will land at $3.77. That&rsquo;s a bit short of the $4.50 posted in 2023. However, revenue may reach $2.63 billion. If so, it would be an 11.5% jump from last year&rsquo;s print of $2.35 billion.</p>



<p>Enticingly, RPRX trades at <a href="https://www.gurufocus.com/stock/RPRX/summary?search=rprx">7.74X trailing-year revenue</a>, below the sector median 9.63X. Also, analysts rate shares a <a href="https://www.tipranks.com/stocks/rprx/forecast">unanimous strong buy</a> with a $44 average price target. Again, it&rsquo;s well worth consideration for undervalued healthcare stocks.</p>



<h2>Voyager Therapeutics (VYGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Another entity falling under the biotech category, <strong>Voyager Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vygr-stock-quote/"><strong>VYGR</strong></a>) focuses on the treatment of gene therapy and neurology diseases. The company&rsquo;s lead clinical candidate is <a href="https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-reports-robust-preclinical-activity-tau">VY-TAU01</a>, an anti-tau antibody program for the treatment of Alzheimer&rsquo;s disease. Its pipeline also includes superoxide dismutase 1 silencing gene therapy, which is being investigated for the treatment of amyotrophic lateral sclerosis (ALS).</p>



<p>One of the exciting factors of VYGR is that it&rsquo;s hit or miss. That&rsquo;s not going to appeal to conservative investors but it should attract speculators. For example, in Q3 of last year, Voyager slightly widened its expected per-share loss of 58 cents by coming in at 59 cents to the red. However, in Q4, the company posted EPS of $1.25, dramatically beating the expected loss of 29 cents per share.</p>



<p>Now, analysts anticipate a rough year in fiscal 2024, projecting an 84% loss on the top line. However, they also forecast a recovery effort in fiscal 2025. Currently, shares trade at 1.72X tangible book value, below the sector median 2.88X.</p>



<p>That seems grossly undervalued considering that experts rate shares a <a href="https://www.tipranks.com/stocks/vygr/forecast">unanimous strong buy</a> with a $16.33 price target. Therefore, it&rsquo;s one of the undervalued healthcare stocks to gamble on.</p>



<h2>Semler Scientific (SMLR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/medical-device-stocks-hospital-stocks-healthcare-stocks-300x169.jpg" alt="An image of two medical professionals performing a procedure on a patient"><div>Source: Roman Zaiets / Shutterstock.com</div></div><p>Operating in the medical devices subsector, <strong>Semler Scientific</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/smlr-stock-quote/"><strong>SMLR</strong></a>) arguably represents the riskiest idea on this list of undervalued healthcare stocks. Per its <a href="https://finance.yahoo.com/quote/smlr/profile">corporate profile</a>, Semler provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers. One of its main products is QuantaFlo, an in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient&rsquo;s vascular condition.</p>



<p>At first glance, SMLR stock appears incredibly relevant. However, the market feels differently, getting severely &ldquo;de-risked&rdquo; earlier in March. One of the issues may have been underperformance in Q4 last year. Back then, Semler posted an EPS of 59 cents against an expected target of 57 cents. However, the positive earnings surprise of Q2 and Q3 came out to a robust 36.55%. By comparison, Q4 was disappointing.</p>



<p>Still, experts are hoping for a recovery year in fiscal 2024. They believe EPS will land at $3.40 on sales of $75.5 million. Last year, per-share profits reached $2.68 on revenue of $68.18 million. Shares trade at <a href="https://www.gurufocus.com/stock/SMLR/summary?search=smlr">10.59X trailing-year revenue without non-recurring items</a>. That&rsquo;s lower than 90.36% of competitors.</p>



<p><a href="https://www.marketscreener.com/quote/stock/SEMLER-SCIENTIFIC-INC-120795486/news/Lake-Street-Adjusts-Semler-Scientific-PT-to-175-From-200-Maintains-Buy-Rating-36870139/">Lake Street believes SMLR could hit $65</a>. If so, it&rsquo;s worth keeping on your radar.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/the-healthcare-bargain-blitz-7-undervalued-stocks-to-inject-into-your-portfolio/">The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

Stock losers of Republican policy if Trump wins - GS

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amphastar Pharmaceuticals (AMPH – Research Report), Ascendis Phar...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)

AMN Healthcare: Where's The Stopping Point?

FHLC: Healthcare Dashboard For April

ABBV

ALKS

AMGN

AMPH

ASND

CACI

CARR

COLL

ENPH

FHLC

FLNC

FSLR

HRMY

INVA

KTOS

LDOS

LNTH

PDCO

RPRX

RSPH

SAIC

SEDG

SMLR

VYGR

Press Releases

AMN Healthcare Named One of America's Most Responsible Companies 2024 by Newsweek

Survey: Majority of Healthcare Executives Foresee Better Organizational Health in 2024

Legal

AMN Healthcare to Hold Fourth Quarter and Full Year 2023 Earnings Conference Call on Thursday, February 15, 2024

AMN Healthcare Named One of America's Greatest Workplaces for Diversity by Newsweek

AMN Healthcare Announces Fourth Quarter and Full Year 2023 Results

SURVEY: 31% of Hospital Nurse Leaders Plan to Change Jobs in the Next Year

AMN Healthcare Sustainability & Social Impact Report Shows Industry-Leading Efforts

AMN Healthcare Enhances Internal Resource Pool Management for Health Systems with Vendor Neutral Technology Capabilities

AMN Healthcare to Hold First Quarter 2024 Earnings Conference Call on Thursday, May 9, 2024

Survey: Physicians Turning to Locum Tenens to Improve Work Conditions, Relieve Burnout

Addus HomeCare Corporation - Common Stock